InternationalResearch and clinical trials
Denecimig under the skin once a week or once a month reduced bleeding in hemophilia A in a phase 3 study
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
Results of a phase 3 study of denecimig, given under the skin, in hemophilia A have been published. Patients aged 12 years and older, with or without inhibitors, took part in the study. The drug was given once a week or once a month, and no clotting problems were reported. In those who previously received treatment only when bleeding occurred, bleeds needing treatment fell by more than 96%. In those who previously received regular factor, bleeds fell by between 43% and 54%.
What does it mean for patients and families?
This is a research result. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
Scientific paper: Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors. New England Journal of Medicine, 2026. DOI: 10.1056/NEJMoa2517384 · PubMed 42054679
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Hemophilia (A and B)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.